Available Online at

http://www.ijcpa.in

April-June 2016

International Journal of CHEMICAL AND PHARMACEUTICAL ANALYSIS

eISSN: 2348-0726 ; pISSN : 2395-2466

Review Article | Volume-3 | Issue-3 | Article ID: 979

REGULATORY REQUIREMENTS FOR OTC MEDICATIONS AS PER US, EUROPE AND AUSTRALIA

Hirenkumar Solanki, Dilip Maheshwari*

Department of Quality Assurance and Pharm Regulatory Affairs, L.J. Institute of Pharmacy, Gujarat Technological University, Ahmadabad, Gujarat - 382210, India

***Corresponding Author:** Email: dgmaheshwari@gmail.com*

Received: 14 March 2014 / Revised: 9 April 2016 / Accepted: 19 April 2016 / Available online : 30 June 2016

ABSTRACT

Indian pharmaceutical area is rising quickly and there is a need of administrative undertakings experts to give the present needs of businesses for the worldwide rivalry. An administrative undertaking is a to some degree new calling which has created from the craving of governments to protect general wellbeing. OTC meds delineate the Quality, Safety and Efficacy of the medication item. To comprehend the security regulations in various nations, as various nations are worried with their own administrative rules to be taken after. Distinctive regulations in light of their administrative rules, they have diverse clinical trials to be done with a specific end goal to accomplish customer wellbeing and adequacy. The territories where government controlling the wellbeing and adequacy of items are pharmaceuticals, veterinary solutions, therapeutic gadgets, pesticides, agrochemicals, beautifying agents and correlative prescriptions. The pharmaceutical organizations in charge of the disclosure, testing, clinical trials, generation, fabricate and advertising of these items likewise need to guarantee that they supply items that are sheltered and make a beneficial commitment to general wellbeing and welfare. Administrative undertakings experts are the connection between pharmaceutical commercial ventures and overall administrative offices. They are required to be knowledgeable in the laws, regulations, rules and direction of the administrative offices. There is a developing need to fuse the present necessities of pharmaceutical commercial ventures in the standard educational modules of drug store schools to set up the understudies with the most recent advancements to serve the businesses.

Keywords *– Regulatory affairs, Pharmaceutical industries, OTC Medications, Quality, Safety and Efficacy.*

1. INTRODUCTION

1.1 Non-Prescription drugs as per USA[1]

In the United States, the production and offer of OTC substances is controlled by the Food and Drug Administration. The FDA requires that every "new medication" acquire a New Drug Application (NDA) before entering interstate trade, however the demonstration exempts any medications for the most part perceived as sheltered and successful (GRAS/E) from this necessity. To manage the unlimited number of OTC medications that were at that point available before the prerequisite that all medications get a NDA, the FDA made the OTC monograph framework to survey classes of medications and sort them as GRAS/E after audit by master boards. This implied certain classes of OTC medications would not be required to get a NDA and could stay available on the off chance that they complied with the monograph rules for measurements, marking, and notices which are settled in the Code of Federal Regulations.

1.2 Medicinal Products for Human Use as per Europe[2-3]

Directive 65/65/EEC of 26 January 1965 on the guess of procurements set around law, regulation or regulatory activity identifying with therapeutic items, Council Directive 75/318/EEC of 20 May 1975 on the estimate of the laws of Member States identifying with investigative, pharmaco-toxicological and clinical norms and conventions in admiration of the testing of exclusive restorative item, Council Directive 75/319/EEC of 20 May 1975 on the estimation of procurements set around law, regulation or managerial activity identifying with restrictive restorative items, Council Directive 89/342/EEC of 3 May 1989 broadening the extent of Directives 65/65/EEC and 75/319/EEC and setting down extra procurements for immunological restorative items comprising of antibodies, poisons or serums and allergens.

1.3 OTC Medications as per AUSTRALIA[4]

Over-the-counter medications (OTC) are pharmaceuticals that are not physician recommended prescriptions and are not correlative meds. OTC medications can be supplied as:

a. Pharmacy solutions (incorporated into Schedule 2 to the Poisons Standard); or
b. Pharmacist-just solutions (incorporated into Schedule 3 to the Poisons Standard); or
c. General deals solutions that are excluded in any of the Schedules to the Poisons Standard.

Medications are assembled into calendars as per the proper level of administrative control over their accessibility to purchasers.

2. NON-PRESCRIPTION DRUG REGULATIONS FOR USA

2.1 About US-FDA[5]

FDA is in charge of assuring so as to ensure the general wellbeing the security, adequacy and security of human and veterinary medications, organic items, restorative gadgets, our country's nourishment supply, beautifiers, and items that transmit radiation.

2.2 CDER

As a feature of the U.S. Sustenance and Drug Administration (FDA), CDER controls over-the-counter and doctor prescribed medications, including organic therapeutics and bland medications. This work covers more than just pharmaceuticals. For instance, fluoride toothpaste, antiperspirants, dandruff shampoos and sunscreens are all considered "medications".

2.3 Requirements for OTC drug products[6-7]

a. Standards for safety and efficacy Standards for safety and efficacy
b. Good Manufacturing Practices (reviews) Good Manufacturing Practices (assessments)
c. Labeling under 21 CFR 201.66 Labeling under 21 CFR 201.66 Also, consumers must be able to Also, consumers must be able to…

- Self-analyze
- Self-treat

d. Self-manage can be assessed through…

- Label understanding studies
- Actual use studies Actual use studies

The improvement of a pharmaceutical is a stepwise process including an assessment of both creature and human viability and wellbeing data. The objectives of the nonclinical wellbeing assessment for the most part incorporate a portrayal of poisonous impacts regarding target organs, measurements reliance, relationship to presentation, and, when suitable, potential reversibility. This data is utilized to assess an underlying safe beginning measurements and dosage range for the human trials and to distinguish parameters for

clinical observing for potential antagonistic impacts. The nonclinical wellbeing examines, albeit generally restricted toward the start of clinical improvement, ought to be sufficient to portray potential unfriendly impacts that may happen under the states of the clinical trial to be bolstered.

2.4 Marketing pathways for an OTC[8]

Two Regulatory Systems

– New Drug Applications (NDA)

– OTC Drug Monographs

2.5 OTC Drugs Developed Through the NDA Process

A backer trying to market its item OTC, either as another NDA or as a change from a medicine item, applies to the Division of Nonprescription Drug Products (DNDP) in the Office of Drug Evaluation IV. DNDP will administer sedate advancement, including the survey and administrative activity on Investigational New Drugs (INDs), and might acquire enter from the particular topic audit division (SSMRD) amid the improvement process. After a patron presents a NDA, DNDP audits the customer studies, the post advertising wellbeing information, the OTC marking, and any administrative issues. The SSMRD works together with DNDP (see MaPP 6020.50) and regularly gives audit of the viability and wellbeing information identified with controlled clinical trials. Extra information is gotten as required from different controls outside of DNDP, including clinical pharmacology, insights, and science.

2.6 OTC Drugs Developed Under the OTC Drug Monograph Process

DNDP is also responsible for the development of the OTC drug monographs. Data supporting the safety and efficacy of OTC active ingredients in a particular drug monograph are reviewed by appropriate scientific personnel. Efficacy data may require the input of a Medical Officer and/or Statistician from a prescription review division. Carcinogenicity or other animal toxicology data may require input from a CDER pharmacologist. So, while DNDP is considered to be the lead division in the development of an OTC drug monograph, reviewers from multiple divisions within the Office of New Drugs (OND) may be involved in this process.



Multi step process

2.7 OTC Drug Facts Label (DFL)[9]

At whatever point you utilize an over-the-counter (OTC) pharmaceutical, perusing the medication item's naming is vital for dealing with yourself and your crew. The mark lets you know what the prescription should do, who ought to or shouldn't take it, and how to utilize

it. The naming of OTC pharmaceuticals has constantly contained use and security data for purchasers. With the presentation of the "Medication Facts" mark, the data is more uniform and less demanding to peruse and get it.

2.8 Safety reporting for OTC drugs

2.8.1 OTC products approved under an ANDA

- Subject to 21 CFR 314.80
- 15-day Alert reports and intermittent reports
- Serious and non-genuine unfriendly encounters (AEs) reported
- Foreign and residential sources
- Follow up reports for any underlying 15-day Alert reports

2.8.2 OTC monograph products

- Subject to section 760 of the FDandC Act (effective in 2007)
- 15-day Alert reports – no occasional reporting
- Only serious AEs reported
- Domestic sources only

3. REGULATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE AS PER EUROPE

3.1 About EMA[10]

The European Medicines Agency's (EMA) primary obligation is the security and advancement of open and creature wellbeing, through the assessment and supervision of drugs for human and veterinary use.

The EMA is in charge of organizing the EU's wellbeing checking or "pharmacovigilance" framework for prescriptions. It always screens the wellbeing of meds through the EU organize and can make a move if data demonstrates that the advantage hazard equalization of a drug has changed since it was approved.

3.2 CHMP[11]

The Committee for Medicinal Products for Human Use (CHMP) is in charge of setting up the Agency's sentiments on all inquiries concerning pharmaceuticals for human use, as per Regulation (EC) No 726/2004.

3.3 Regulations for Medicinal Products for Human Use

3.3.1 Safety and Efficacy Requirements[12]

The danger to subject security in a clinical trial for the most part comes from two sources: the investigational therapeutic item and the intercession. Numerous clinical trials, be that as it may, posture just a negligible extra hazard to subject wellbeing contrasted with ordinary clinical practice. This is especially the situation where the investigational restorative item is secured by a promoting authorisation, that is the quality, wellbeing and viability has as of now been evaluated throughout the showcasing authorisation strategy" or, if that item is not utilized as a part of understanding with the terms of the advertising authorisation, that utilization is confirmation based and upheld by distributed logical proof on the security and adequacy of that item, and the intercession postures just extremely restricted extra hazard to the subject contrasted with typical clinical practice. Those low-intercession clinical trials are frequently of pivotal significance for evaluating standard medications and analyses, along these lines enhancing the utilization of therapeutic items and in this way adding to an abnormal state of general wellbeing. Those clinical trials ought to be liable to less stringent standards, as respects checking, prerequisites for the substance of the expert document and traceability of investigational

restorative items. Keeping in mind the end goal to guarantee subject wellbeing they ought to however be liable to the same application method as some other clinical trial.

3.3.2 Marketing Authorization process[13]

The Committee for Human Medicinal Products (CHMP) assess the applications got by the EMEA. In perspective of the candidate's inclination, CHMP contracts out appraisal work in one of the part expresses (the "rapporteur"). After the complete appraisal, the CHMP convey conclusion to EU Commission inside 210 days. The EU Commission asks for remarks from other part states, if a positive sentiment from CHMP is gotten. The other part states can react in around 28 days. At the point when a permit is prescribed, an European Public Assessment Report (EPAR) is created and promoting authorisation is issued. This authorisation is substantial all through the European Union and is for a long time, be that as it may, the expansion can be connected to the EMEA three months before the lapse of this period. Figure speak to the concentrated method for promoting approval.

3.3.3 Decentralized Procedure

With a specific end goal to acquire promoting approvals in a few part expresses, the brought together system is not obligatory; in such case the decentralized methodology is to be utilized. An application is submitted to able powers of each of the part states, where an advertising approval is to be looked for. The data like quality, viability, wellbeing, regulatory data should be submitted and a rundown of all Concerned Member States (CMSs) and one part state to go about as Reference Member State (RMS). A draft appraisal report on the therapeutic item is readied and the CMSs and the RMS accept the application inside of a time allotment of 14 days. The RMS get ready draft synopsis of item qualities, naming and bundle pamphlet inside of 120 days. This report can be affirmed inside of 90 days. Be that as it may, if a restorative item should bring about potential genuine danger to general wellbeing, CMS(s) will advise to different CMS, RMS and candidate and further choice in such manner is taken inside of 30 days. Inside of 60 days of the correspondence of the purposes of contradiction, every single part state range to a concurrence on the move to be made. In the wake of coming to an assention of the part expresses, the RMS records the understanding and advises to the candidate. Be that as it may, if the part states couldn't achieve an understanding, then CHMP intercedes and take a definite choice keeping in perspective of the composed or oral clarifications of the candidate. Figure speak to the decentralized methodology for promoting approval in EU.

3.3.4 National Procedure

This kind of approval is conceded on nation by-nation premise by the skillful powers, in every part state. Items planned for one market and not obliged to utilize the concentrated method.

3.3.5 Mutual Recognition Procedure

The common acknowledgment system (MRP) is like the de-brought together methodology with a few contrasts. The shared acknowledgment system is material to therapeutic items which have gotten a promoting approval in any part state while the decentralized strategy is pertinent to those items which were never endorsed in any part conditions of the European Union. The MRP is utilized to get advertising approvals in different a few part states. The assessment of use by RMS can be taken inside of 90 days rather than 120 days (in decentralized strategy). After the stipend of advertising approval, the item can be promoted, which might be called as Phase IV trials, wherein new uses or new populaces, long haul impacts and so forth can be investigated.

3.3.6 Drug Label[14]

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use.

According to Article 54

The following particulars shall appear on the outer packaging of medicinal products or, where there is no outer packaging, on the immediate packaging:

The name of the restorative item took after by its quality and pharmaceutical structure, and, if suitable, whether it is proposed for infants, kids or grown-ups; where the item contains up to three dynamic substances, the universal non-exclusive name (INN) might be incorporated, or, if one does not exist, the regular name;

i. A explanation of the dynamic substances communicated subjectively and quantitatively per measurements unit or as per the type of organization for a given volume or weight, utilizing their basic names;
ii. The pharmaceutical structure and the substance by weight, by volume or by number of measurements of the item;
iii. A rundown of those excipients known not a perceived activity or impact and incorporated into point by point direction distributed as per Article. In any case, if the item is injectable, or a topical or eye planning, all excipients must be expressed;
iv. The technique for organization and, if fundamental, the course of organization. Space should be accommodated the endorsed dosage to be shown;
v. A extraordinary cautioning that the restorative item should be put away out of the scope and sight of youngsters;
vi. A extraordinary cautioning, if this is fundamental for the restorative item;
vii. The expiry date in clear terms (month/year);
viii. Special capacity precautionary measures, if any;
ix. Specific precautionary measures identifying with the transfer of unused therapeutic items or waste got from restorative items, where fitting, and in addition reference to any proper gathering framework set up;

3.3.7 Periodic safety reports

DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use

According to Article 107b

Marketing authorisation holders shall submit to the Agency periodic safety update reports containing:

(a) Summaries of information important to the banquet and dangers of the restorative item, including consequences of all studies with a thought of their potential effect on the promoting authorisation;

(b) An investigative assessment of the danger advantage parity of the restorative item;

(c) All information identifying with the volume of offers of the restorative item and any information possessing the showcasing authorisation holder identifying with the volume of solutions, including an appraisal of the populace presented to the therapeutic item.

4. REGULATIONS FOR OTC MEDICATIONS FOR AUSTRALIA

4.1 About TGA[15-16]

The TGA is in charge of guaranteeing that helpful products accessible for supply in Australia are sheltered and fit for their expected reason. These incorporate merchandise Australians depend on consistently, for example, vitamin tablets and sunscreens, through to products used to treat genuine conditions, for example, professionally prescribed prescriptions, immunizations, blood items and surgical inserts.

4.2 TGA regulates

The Act requires that every medicinal item to be foreign made into, supplied in, or sent out from Australia (other than those that are absolved) must be incorporated into the Australian Register of Therapeutic Goods (ARTG).

4.3 Advisory Committee on Non-prescription Medicines (ACNM)[17]

4.4 Australian regulatory guidelines for OTC medicines (ARGOM)[18]

These Guidelines portray the data to be supplied with an application for enlistment of OTC (over-the-counter) solutions in the Australian Register of Therapeutic Goods (ARTG). These drugs will be liable to assessment by the Therapeutic Goods Administration, as per Section 25 of the Therapeutic Goods Act 1989

4.5 ARGOM guidelines

- Guidelines on efficacy and safety aspects of OTC applications
- Guidelines on quality parts of OTC applications
- Guidelines on presentation parts of OTC applications
- Guidelines on OTC applications for new substances
- Guidelines on OTC applications for particular substances

4.6 Guidelines on efficacy and safety aspects of OTC applications[19]

The Therapeutic Goods Act 1989 (the Act) requires that applications for an item enlistment be assessed "having respect to whether the quality, wellbeing and viability of the merchandise for the reasons for which they are to be utilized have been tastefully settled".

All applications for over-the-counter (OTC) pharmaceutical enrollment must be bolstered by confirmation to substantiate the wellbeing and viability of the item. This part of the direction report depicts the sorts of proof that ought to be submitted for the different OTC solution applications.

4.7 Guidelines on quality aspects of OTC applications[20]

The Therapeutic Goods Act 1989 (the Act) requires that applications for an item enlistment be assessed "having respect to whether the quality, wellbeing and adequacy of the merchandise for the reasons for which they are to be utilized have been agreeably settled".

All applications for over-the-counter (OTC) drug enlistment must be upheld by confirmation to substantiate the nature of the item. This part of the direction report portrays the data in regards to the nature of the item ought to be submitted for OTC pharmaceutical applications.

4.8 ARGOM: Guidelines on the pre-market application and evaluation process for OTC medicines[21]

The OTC prescription assessment procedure is comprised of five stages appeared in Figure. Every period of the procedure incorporates characterized prerequisites for advancing to the following stage. The general process and stages are taken after for all application levels, despite the fact that there are contrasts in the prerequisites inside of every stage.

The accompanying standards apply to the procedure:

- Applications are to be submitted electronically in CTD design for both new drug applications and applications to change a prescription. The application configuration is liable to arranged execution in the new process.
- Applications are screened by the TGA upon receipt.
- Incomplete applications, including applications erroneously surveyed similar to a lower application level, are not acknowledged for assessment and the application expenses are relinquished. This is liable to organized usage in the new process.
- There are a predetermined number of events for solicitations from the TGA for the candidate to give elucidation or location issues that have been distinguished.
- Sponsors will be given a predefined time period in which to react to asks for from the TGA to give elucidation or location issues that have been distinguished.

- There will be no chance to submit new information or roll out improvements to the application after accommodation, unless particularly asked for by the TGA or in the event that it is wellbeing information.
- The assessment is planned to be finished inside of a predefined target time. Data with respect to target times for every stage can be situated on the TGA site.
- The representative will settle on a choice after the assessment stage. The choice is intended to be finished inside of the predetermined target time.

4.9 Drug Label[22]

The reason for a solution mark is to give data about the item, for example, its personality, intensity, content, stockpiling, expiry date, enlistment status and patron. Medication marks additionally incorporate other data not required by the Order, but rather which might be required by other authoritative instruments or for business purposes. These incorporate things, for example, signal headings (eg. Remedy just, drug specialist just), standardized tags and patron's logos.

4.10 Monitoring the safety of OTC products

The TGA has a multi-faceted program for monitoring therapeutic products that are on the market.

- **The TGA has an issue reporting framework for reporting:**
- Medicine inadequacy or deformity

  Adverse response to a prescription
- Once an issue has been distinguished conceivable administrative activities change from kept observing to pulling back the item from the business sector. Moves the TGA can make include:
- **Informing medicinal services experts and shoppers about the dangers of utilizing the item**
- Re-evaluating the advantage hazard profile
- Requiring item marking changes
- Requiring outline or assembling change
- Recalling items
- Removal of the item from the ARTG



Figure 1: Market Authorisation NDA Process[23]



Figure 2: OTC DRUG FACTS LABEL (DFL)



Figure 3: Centralized Procedure[24]



Figure 4: Decentralized Procedure[25]



Figure 5: Mutual Recognition Procedure[26]

Figure 6 : pre-market application and evaluation process for OTC medicines

5. CONCLUSION

Administrative Affairs Profession trust the new way to deal with regulation will in the long run embraced for all medicinal services items as it speaks to the best model for conveying new social insurance advances to advertise in a sensible time with worthy wellbeing. Most organizations, whether they are major multinational pharmaceutical partnerships or little, inventive biotechnology organizations, have pro bureaus of Regulatory issues experts and Regulatory undertakings office is always developing the one which is slightest affected amid the securing and merger, furthermore amid subsidence. Because of the changing assets important to satisfy the administrative prerequisites, a few organizations likewise outsource or out undertaking administrative issues to outside administration suppliers. In today's focused surroundings the diminishment of the time taken to achieve the business sector is basic to an item's and thus inside of the organization's for their prosperity and development. The best possible behavior of its Regulatory Affairs exercises is subsequently of significant financial significance for the organization.

6. ACKNOWLEDGEMENT

The authors are highly thankful to Dr. K. Pundarikakshudu, Director of L. J. Institute of Pharmacy, Ahmadabad, India for providing all the facilities to carry out the research work.

7. REFERENCES

1. U.S. Food and Drug Administration, Protecting and Promoting Public Health, July 2014, www.fda.gov
2. EUROPEAN MEDICINES AGENCY Science Medicine Health, 2004, http://www.ema.europa.eu
3. DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on community code relating to, “medicinal products for human use”, 6 November 2001, OJ L 311, 28.11.2001, p. 67.
4. Australian regulations for over-the-counter, 18 August 2015, https://www.tga.gov.au/australian-regulation-over-counter-medicines#whatis
5. U.S. Food and Drug Administration, Protecting and Promoting Public Health, 12/07/2015 http://www.fda.gov/AboutFDA/WhatWeDo/
6. Regulation of Over-the-Counter (OTC) Drug Products, 2015, http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM148055.pdf
7. U.S. Food and Drug Administration, April 30 2004, http://www.fda.gov/downloads/drugs/newsevents/ucm167308.pdf
8. Drug Applications for Over-the-Counter, 12/30/2014, http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/ucm209647.htm
9. OTC DRUG FACTS LABEL (DFL), 06/05/2015, http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143551.htm
10. European Medicines Agency, 26/08/2014, http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000091.jspandmid=WC0b01ac0580028a42

11. CHMP: Overview, 2007, http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000095.jspandmid=WC0b01ac0580028c7a
12. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (OJ L 121, 1.5.2001, p. 34)
13. Bianchetto MA, "Overview of the Authorisation procedures for Medicinal Products", chapter 17, pg 151-168.
14. THE EUROPEAN PARLIAMENT AND OF THE COUNCIL, "on the Community code relating to medicinal products for human use", 6 November 2001, http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf
15. Australian Government, Department of Health, 9 December 2015, https://www.tga.gov.au/what-tga-regulates
16. Australian regulations for over-the-counter medicines, 9 December 2015, https://www.tga.gov.au/australian-regulation-over-counter-medicines
17. Advisory committee on Non-prescription Medicines, 27 January 2016, https://www.tga.gov.au/committee/advisory-committee-non-prescription-medicines-acnm
18. Australian regulatory guidelines for OTC medicines, 1 March 2016, https://www.tga.gov.au/publication/australian-regulatory-guidelines-otc-medicines-argom
19. Guideline on efficacy and safety aspects of OTC applications, 1 March 2016, https://www.tga.gov.au/book/export/html/5284
20. Guideline on quality aspects of OTC applications, 30 May 2014, https://www.tga.gov.au/publication/australian-regulatory-guidelines-otc-medicines-argom
21. Guidelines on the pre-market application and evaluation process for OTC medicines, April 2014, https://www.tga.gov.au/book/otc-pre-market-evaluation-process
22. General requirements for labels for medicines, 27/08/2001, https://www.comlaw.gov.au/Details/F2009C00264/Download
23. New Drug Application, 02/03/2015, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/
24. Drug Approval Process for Europe, 2014, https://www.google.co.in/imgres?imgurl=http://image.slidesharecdn.com/seminarpresentations14thmay2015autosaved-150514091639-lva1app6891/95/regulations-for-drug-approval-in-usa-eu-india-27-638.jpg%253Fcb%253D1434946792andimgrefurl=http://www.slideshare.net/DrPankajBablani/seminar-presentations-14th-may-2015-autosaved-48137557andh=479andw=638andtbnid=5J7PEsiJApzgmM:anddocid=bPd3pEY_f-ojhMandei=wSmvVs6rEYjvugSIxbbwCwandtbm=ischandved=0ahUKEwiOkIa3pNbKAhWIt44KHYiiDb4QMwgfKAQwBA
25. Drug Approval Process for Europe, 2014, https://www.google.co.in/search?q=decentralized+procedureandbiw=1366andbih=667andsource=lnmsandtbm=ischandsa=Xandved=0ahUKEwiRn_TjqNbKAhVBC44KHfX7AggQ_AUIBigB#imgrc=4IU5EPOoxiXtGM%3A
26. Drug Approval Process for Europe, 2014, https://www.google.co.in/search?q=mutual+recognition+procedureandbiw=1366andbih=623andsource=lnmsandtbm=ischandsa=Xandsqi=2andved=0ahUKEwijrYO2qNbKAhVHTY4KHdoFBfsQ_AUICCgD#imgrc=q09PQT3vA0rbqM%3A